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Nitric oxide (NO) has been shown to contribute to the pathogenesis of influenza virus-induced pneumonia
in mouse models. Here we show that replication of influenza A and B viruses in Mabin Darby canine kidney
cells is severely impaired by the NO donor, S-nitroso-N-acetylpenicillamine. Reduction of productively infected
cells and virus production proved to correlate with inhibition of viral RNA synthesis, indicating that NO affects
an early step in the replication cycle of influenza viruses.
Nitric oxide (NO), a gaseous free radical has been shown to
have multiple biological functions. NO is catalytically gener-
ated by one of the three isoforms of NO synthase (NOS) from
L-arginine. eNOS and nNOS, which are produced in endothe-
lial cells and neuronal cells, have been shown to play a role in
vasodilatation and neurotransmission, respectively, whereas
NO generated by iNOS (NOS2), the inducible form of NOS,
has been shown to play a role in the defense against a variety
of microbial pathogens, including bacteria, parasites (for a
review, see reference 24), and viruses, including herpes simplex
virus type 1 (HSV-1), vesicular stomatitis virus, Japanese en-
cephalitis virus, poliovirus, murine hepatitis virus, murine leu-
kemia virus, coxsackievirus, ectromelia virus, rhinovirus, and
vaccinia virus (3, 5, 6, 11, 15, 19, 20, 29, 31, 37).
Although the mode of action of NO is not fully understood,
it has been shown that NO can affect the function of iron- and
thiol-containing proteins (18, 25, 28), such as guanylate cyclase,
ribonucleotide reductase, aconitase, and mitochondrial elec-
tron transport enzymes (22). iNOS can be induced in a number
of different cell types by cytokines or bacterial products. It has
been demonstrated that iNOS is expressed in murine macro-
phages (36), mouse T cells (35), human hepatocytes (7), alve-
olar macrophages (26), and mononuclear cells (33). NO can
also be released from human airway epithelial cells, the pri-
mary target for influenza viruses, after stimulation with gamma
interferon, interleukin 1b (IL-1b), and tumor necrosis factor
alpha (TNF-a) (4, 10, 32). Interestingly, the production of
these cytokines is induced shortly after infection with influenza
viruses (12, 13, 34). Furthermore, it has been demonstrated
that the expression of the hemagglutinin (HA) of influenza
viruses can activate NF-kB, a transcription factor which has
been shown to regulate the expression of a number of cytokine
genes, including the TNF-a and IL-1b genes (27).
Although studies in mouse models have indicated that the
release of NO after infection with influenza viruses also con-
tributes to the pathogenesis of influenza virus-induced pneu-
monia, it may be argued that the production of NO in the
respiratory tract may also provide a first-line defense mecha-
nism against influenza viruses. Since to date it is not known
whether influenza virus replication is sensitive to the action of
NO, we studied the effect of S-nitroso-N-acetylpenicillamine
(SNAP) on influenza replication in vitro. SNAP is the nitrosy-
lated form of L-acetylpenicillamine and immediately donates
NO when added to culture medium (14).
Mabin Darby canine kidney (MDCK) cells were infected at
different multiplicities of infection (MOI) with influenza vi-
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FIG. 1. Addition of the NO donor SNAP inhibits the replication of influenza
A and B viruses in a dose-dependent manner. MDCK cells were infected with
influenza virus A/Netherlands/202/95 at an MOI of 0.3 (A). The culture super-
natants were assayed for hemagglutination activity 24 h postinfection. MDCK
cells were also infected with influenza virus B/Netherlands/22/95 with an MOI of
0.03 (B). The culture supernatants were analyzed for HA 48 h postinfection.
Using Griess reagent, the release of NO from SNAP was demonstrated by
detection of its metabolite nitrite (C). The infected cells were treated with the
indicated concentrations of SNAP (E) or NAP (F).
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ruses and immediately after infection were treated with differ-
ent doses of SNAP or a control molecule which lacks the
NO-donating S-nitroso group, N-acetylpenicillamine (NAP).
SNAP and NAP were added in a dose range which was found
to inhibit the replication of other viruses (3, 5, 15, 19, 29). The
experiments were performed twice and the results of represen-
tative experiments are shown in Fig. 1 and 2. SNAP inhibited
the replication of both influenza A (A/Netherlands/202/95
[H3N2]) and influenza B (B/Netherlands/22/95) viruses in a
dose-dependent fashion as shown by measuring the HA titers
released in the culture supernatants of infected cells (Fig. 1).
The observed inhibitory effects correlated with the release of
NO2
2, an intermediate metabolite of NO, in the culture me-
dium, as determined with Griess reagent (8). The strongest
inhibition was observed by using SNAP at a concentration of
400 mM. The reduction of HA titer also correlated with a
reduction of the release of infectious virus into the culture
supernatants of MDCK cells infected with influenza virus
A/Netherlands/202/95 (Fig. 2). Twenty-four hours postinfec-
tion, the inhibitory effect of NO was most pronounced using a
low MOI for the infection of the MDCK cells. The addition of
SNAP to the cultures did not affect the viability of MDCK cells
as determined by the trypan blue exclusion method, and the
replication of the MDCK cells was slightly reduced. The cell
number in untreated cultures increased from 2.1 3 106 to 2.9 3
106 per well in 24 h, while in the presence of 400 mM SNAP,
the increase was from 1.7 3 106 to 2.1 3 106. Neuraminidase
FIG. 2. The addition of the NO donor SNAP inhibits the release of infectious
virus into the culture supernatant. MDCK cells were infected with influenza virus
A/Netherlands/202/95 at the indicated MOI and subsequently treated with 400
mM SNAP or NAP or left untreated. The measurement of infectious virus in
culture supernatants of the cells was performed by limiting dilution analysis and
expressed as 50% tissue culture infective doses per milliliter (TCID50/ml) as
previously described (30).
FIG. 3. The number of influenza virus-infected MDCK cells is affected by the addition of SNAP to the cultures before or after infection. SNAP or NAP was added
at the indicated concentrations 3 h before infection or 1 h after infection of the cells with influenza virus A/Netherlands/18/94 at an MOI of 1.0. Twelve hours
postinfection, the cells were fixed with acetone and incubated with a monoclonal antibody specific for the nucleoprotein.
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and hemagglutination activities were also not affected by the
direct addition of SNAP to the virus preparations (data not
shown). In addition to SNAP, the effect of two other NO-
donating molecules, sodium nitroprusside (SNP) and 3-mor-
pholinosydnonimine (SIN-1), was also tested. It was found that
SNP and SIN-1 inhibited replication of influenza virus A/Neth-
erlands/18/94 (H3N2) at a concentration of 100 mM, which was
found to be inhibitory for the replication of other viruses (3),
confirming the inhibitory effect of NO.
This inhibitory effect of NO on influenza virus replication
was further demonstrated by analyzing influenza virus-infected
cells in an immunofluorescence assay using monoclonal anti-
bodies specific for the nucleoprotein (Imagen A and B; Dako-
pats) and in RNA hybridization assays (30). To this end,
MDCK cells were infected with influenza virus A/Netherlands/
18/94 (H3N2) at an MOI of 1.0 and treated with different doses
of SNAP or NAP immediately after or 3 h prior to infection.
Compared with untreated control cultures, the number of in-
fected cells was clearly reduced in SNAP treated cultures, but
not in cultures treated with NAP (Fig. 3). The inhibition of
hemagglutination activity and the release of infectious virus in
the supernatants of these cultures by the addition of SNAP
paralleled the inhibition observed with influenza virus A/Neth-
erlands/202/95 in the experiments described above (data not
shown).
To identify which step in the replication cycle of influenza
virus was inhibited, the synthesis of vRNA and mRNA encod-
ing the proteins HA and NP was monitored in parallel by an
RNA hybridization assay using digoxigenin (DIG)-labelled
RNA probes specific for negative- and positive-sense HA and
NP RNA molecules and b-actin mRNA. The latter probe was
transcribed from the pBluescript plasmid containing the b-ac-
tin coding sequence (9), as described previously (30). The
addition of the NO donor 3 h prior to infection significantly
reduced the synthesis of both vRNA and mRNA (Fig. 4).
When SNAP was added 1 h postinfection, inhibition of RNA
synthesis was also observed, although it was less pronounced.
Levels of b-actin mRNA were not significantly affected by the
addition of SNAP, indicating that the transcriptional activity
and mRNA stability of the MDCK cells were not influenced by
NO.
Taken together, the data presented demonstrate that NO
inhibits the replication of influenza viruses, probably during
the early steps of the virus replication cycle, involving the
synthesis of vRNA and mRNA encoding viral proteins. There-
fore we hypothesize that the production of NO by iNOS in
airway epithelial cells, induced by cytokines which are known
to be synthesized shortly after infection with influenza viruses
by NK cells and macrophages (12, 13), provides an antiviral
effect in these cells. This mechanism would reduce primary
replication of influenza viruses before other effector mecha-
nisms of the immune system, such as those mediated by B and
T lymphocytes, are activated to control the infection. To be
beneficial for the host, the production of NO must be tightly
FIG. 4. The synthesis of virus-specific positive strand (mRNA and cRNA) and negative strand (vRNA) is impaired by the addition of SNAP to the cultures. SNAP
(S) or NAP (N) was added to the cultures at the indicated concentrations 3 h before or immediately after infection with influenza virus A/Netherlands/18/94. Untreated
cultures were included as controls (C). MDCK cells were infected at an MOI of 1.0 and RNA was extracted 12 h postinfection. Threefold serial dilutions of the RNA
preparations were transferred to the membranes and subsequently hybridized to DIG-labelled RNA probes specific for positive-sense HA or NP mRNA/cRNA,
negative-sense HA and NP vRNA, and positive-sense b-actin RNA, which was included as a control for cellular mRNA, as described previously (30).
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regulated to exert antiviral rather than harmful effects, such as
cell death and tissue destruction. This regulation of NO pro-
duction could be at the transcriptional and the translational
level but also at the level of enzyme activity during infection, as
was demonstrated in a mouse-Cryptococcus neoformans model
(21). At present, it is unclear whether the level of in vivo-
synthesized NO compares to the level of NO released from NO
donors in vitro. Only recently, limited information has become
available on the induction of NO after respiratory virus infec-
tions, including influenza (17, 23). The contribution of NO to
the pathogenesis of influenza virus-induced pneumonia of
mice (2, 16) was also observed in HSV-1-induced pneumonia
in this species (1). However, a clear antiviral effect of NO was
also demonstrated against the latter virus in vitro (6, 15). This
pathological effect of NO in virus-induced pneumonia may be
specific for mouse models for pneumonia, since the peak of
exhaled NO in experimentally infected humans was not asso-
ciated with the clinical symptoms of these individuals (23).
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